{"id":410655,"date":"2021-01-07T14:03:15","date_gmt":"2021-01-07T19:03:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=410655"},"modified":"2021-01-07T14:03:15","modified_gmt":"2021-01-07T19:03:15","slug":"elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        <em>Elucida will also participate in the BIO Partnering @\u00a0JPM\u00a0event<\/em>\n      <\/p>\n<p align=\"justify\">MONMOUTH JUNCTION, N.J., Jan.  07, 2021  (GLOBE NEWSWIRE) &#8212; Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno Germano, CEO and President of Elucida Oncology, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021\u00a0at 11:35 a.m. EST.<\/p>\n<p align=\"justify\">Mr. Germano will provide an overview of Elucida Oncology\u2019s novel ultra-small C\u2019Dot drug delivery platform and how it is designed to address the limitations of antibody-drug-conjugates and more traditional drug carriers. The company\u2019s C\u2019Dot-Drug-Conjugates, or CDCs, are novel therapeutics formulated to substantially improve the delivery of a broad range of cancer drugs preferentially to tumor cells in the body, with the potential for markedly lower systemic exposure due to their unique Target or Clear\u2122 properties.<\/p>\n<p align=\"justify\">A live webcast of the presentation will be available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zcr2tYhRyi5YyblfKfEtizuG_UrgFnVZeML-zDKCe6-kIK2Gds2ZJAUQG88r076ZAQQimmrai-UtBa15PXQLgzvLipFhw-8Qsfp5R3tcSzw7CcSUcmZzY4wVVre41BYM30lDDP7UT6Ysh9lriaCEIjbNzts3UzAsXUK7YNjwqldRXFT1AZjLJ7kM55uZaU26\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a> and on the News &amp; Media section of the company\u2019s website. A replay of the presentation will be available for 30 days following the conference.<\/p>\n<p align=\"justify\">Mr. Germano will also participate at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Bc5HKitFupY49ERBNPHR0s7Y8y2F-FgrYJgxcroNtNluthNgH0y-sBXaS9O6CQ9EtqQMAv3_etO1YbYw5mrKBr2wflyFQjzoyicYuF-xIClt1_9MJLg8tt3MnOHNrNO8\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">BIO Partnering @ JPM<\/a> from January 11-15, 2021. Elucida will hold virtual one-on-one meetings throughout this event.<\/p>\n<p align=\"justify\">\n        <strong>About Elucida Oncology<\/strong>\n      <\/p>\n<p align=\"justify\">Elucida Oncology, Inc., is a biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small C\u2019Dot drug delivery platform. The company\u2019s C\u2019Dot-Drug-Conjugates, or CDCs, are novel therapeutics formulated to substantially increase the concentration of highly potent drugs in difficult to treat tumors with minimal systemic exposure due to their unique Target or Clear\u2122 properties. CDCs are designed to enable precise tumor targeting and deep tumor penetration resulting in enhanced efficacy with reduced off-target toxicity, thereby addressing the limitations of antibody-drug-conjugates and more traditional drug carriers. For more information on Elucida Oncology, Inc., please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PDf0f_ZZJbargNlAOaas6hPp38eUkHzqJe5g4E63ulbi0fMgnjoGa1Y3gWUfBk9vzAWeQHXH0aRV5HHxQgGrpzu4QF8nzcD8hDFtSQR7RFw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.elucidaoncology.com<\/a>.<\/p>\n<p>Contact Info:<br \/>media@elucidaoncology.com<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjM1MSMzOTA4MjQ3IzIyMDM3ODc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ab83bd66-dae9-4c3c-bc1c-c79fa1c34fbf\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Elucida will also participate in the BIO Partnering @\u00a0JPM\u00a0event MONMOUTH JUNCTION, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) &#8212; Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno Germano, CEO and President of Elucida Oncology, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021\u00a0at 11:35 a.m. EST. Mr. Germano will provide an overview of Elucida Oncology\u2019s novel ultra-small C\u2019Dot drug delivery platform and how it is designed to address the limitations of antibody-drug-conjugates and more traditional drug carriers. The company\u2019s C\u2019Dot-Drug-Conjugates, or CDCs, are novel therapeutics formulated to substantially improve the delivery of a broad range of cancer drugs preferentially to tumor cells in the body, with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-410655","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Elucida will also participate in the BIO Partnering @\u00a0JPM\u00a0event MONMOUTH JUNCTION, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) &#8212; Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno Germano, CEO and President of Elucida Oncology, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021\u00a0at 11:35 a.m. EST. Mr. Germano will provide an overview of Elucida Oncology\u2019s novel ultra-small C\u2019Dot drug delivery platform and how it is designed to address the limitations of antibody-drug-conjugates and more traditional drug carriers. The company\u2019s C\u2019Dot-Drug-Conjugates, or CDCs, are novel therapeutics formulated to substantially improve the delivery of a broad range of cancer drugs preferentially to tumor cells in the body, with &hellip; Continue reading &quot;Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-07T19:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjM1MSMzOTA4MjQ3IzIyMDM3ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2021-01-07T19:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":320,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjM1MSMzOTA4MjQ3IzIyMDM3ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjM1MSMzOTA4MjQ3IzIyMDM3ODc=\",\"datePublished\":\"2021-01-07T19:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjM1MSMzOTA4MjQ3IzIyMDM3ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjM1MSMzOTA4MjQ3IzIyMDM3ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"Elucida will also participate in the BIO Partnering @\u00a0JPM\u00a0event MONMOUTH JUNCTION, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) &#8212; Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno Germano, CEO and President of Elucida Oncology, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021\u00a0at 11:35 a.m. EST. Mr. Germano will provide an overview of Elucida Oncology\u2019s novel ultra-small C\u2019Dot drug delivery platform and how it is designed to address the limitations of antibody-drug-conjugates and more traditional drug carriers. The company\u2019s C\u2019Dot-Drug-Conjugates, or CDCs, are novel therapeutics formulated to substantially improve the delivery of a broad range of cancer drugs preferentially to tumor cells in the body, with &hellip; Continue reading \"Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-07T19:03:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjM1MSMzOTA4MjQ3IzIyMDM3ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference","datePublished":"2021-01-07T19:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":320,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjM1MSMzOTA4MjQ3IzIyMDM3ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","name":"Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjM1MSMzOTA4MjQ3IzIyMDM3ODc=","datePublished":"2021-01-07T19:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjM1MSMzOTA4MjQ3IzIyMDM3ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjM1MSMzOTA4MjQ3IzIyMDM3ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elucida-oncology-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=410655"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410655\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=410655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=410655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=410655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}